PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

Logo of blackwellopenThis ArticleFor AuthorsLearn MoreSubmit
International Journal of Clinical Practice
 
From:
doi: 10.1111/j.1742-1241.2008.01714.x

Table 5

Summary of results for primary and secondary efficacy variables after 12 weeks of treatment with darifenacin or darifenacin + BMP for the ITT population

DarifenacinDarifenacin + BMP


n = 184n = 195Comparison
ΔMicturition episodes per day
Mean ± SD−2.96 ± 2.91−2.82 ± 2.87
Median (95% CI)−2.67 (−3.33, −2.00)−2.67 (−3.00, −2.33)
H–L difference (95% CI)0.00 (−0.67, 0.33)
p-value0.681
ΔUUI episodes per day
Mean ± SD−1.89 ± 2.29−2.10 ± 2.32
Median (95% CI)−1.33 (–2.00, −1.00)−2.00 (−2.00, −1.33)
H–L difference (95% CI)0.33 (−0.00, 0.67)
p-value0.268
ΔUrgency episodes per day
Mean ± SD−2.87 ± 3.59−2.68 ± 3.54
Median (95% CI)−2.33 (−3.00, −1.67)−2.67 (−3.00, −2.00)
H–L difference (95% CI)0.00 (−0.67, 0.67)
p-value0.882
ΔPads used per day
Mean ± SD−0.72 ± 1.54−0.61 ± 1.28
Median (95% CI)0 (0, 0)0 (0, 0)
H–L difference (95% CI)0.00 (0.00, 0.00)
p-value0.978
ΔNocturnal voids per day
Mean ± SD−0.65 ± 1.26−0.67 ± 1.21
Median (95% CI)−0.67 (−0.67, −0.33)−0.67 (−0.67, −0.33)
H–L difference (95% CI)0.0 (−0.00, 0.33)
p-value0.315

BMP, Behavioural Modification Programme; ITT, intent-to-treat; Δ, change from baseline; UUI, urge urinary incontinence; H–L, Hodges–Lehmann. p-values are based on Wilcoxon rank-sum test, adjusting for baseline severity.